Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma Jun 01, 2023 7:57am EDT
Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting May 26, 2023 5:10pm EDT
Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update May 15, 2023 4:13pm EDT
Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169 Apr 07, 2023 6:50pm EDT
Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update Mar 30, 2023 6:10pm EDT
Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4 Mar 09, 2023 10:02am EST
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting Dec 02, 2022 5:02pm EST
Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISI’s 5th Annual HealthCONx Conference and Piper Sandler’s 34th Annual Healthcare Conference Nov 23, 2022 4:30pm EST
